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Abstract: Effector CD8+ T cell activation and its cytotoxic function are positively correlated with
improved survival in breast cancer. tRNA-derived fragments (tRFs) have recently been found to
be involved in gene regulation in cancer progression. However, it is unclear how interactions
between expression of tRFs and T cell activation affect breast cancer patient survival. We used
Kaplan–Meier survival and multivariate Cox regression models to evaluate the effect of interactions
between expression of tRFs and T cell activation on survival in 1081 breast cancer patients. Spearman
correlation analysis and weighted gene co-expression network analysis were conducted to identify
genes and pathways that were associated with tRFs. tRFdb-5024a, 5P_tRNA-Leu-CAA-4-1, and ts-49
were positively associated with overall survival, while ts-34 and ts-58 were negatively associated
with overall survival. Significant interactions were detected between T cell activation and ts-34 and
ts-49. In the T cell exhaustion group, patients with a low level of ts-34 or a high level of ts-49 showed
improved survival. In contrast, there was no significant difference in the activation group. Breast
cancer related pathways were identified for the five tRFs. In conclusion, the identified five tRFs
associated with overall survival may serve as therapeutic targets and improve immunotherapy in
breast cancer.
Keywords: breast cancer; T cell activation score; tRNA-derived fragments; pathway enrichment
analysis; cancer survival
1. Introduction
Recently, tRNA-derived fragments (tRFs), a novel class of small non-coding RNAs derived from
tRNA precursor or mature sequences, have drawn great attention to characterize their biological
roles and functional mechanisms in diseases. tRFs play important roles in cancer progression and
tumorigenesis [1–4]. Dysregulation of tRFs have been observed in breast cancer [5–8]. For example,
a novel class of tRFs induced by hypoxic stress was found to bind to the oncogenic RNA-binding protein
YBX1 and inhibit the stability and expression of multiple oncogenic transcripts by displacing their 3′
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UTRs from YBX1, which resulted in an antagonized protein activity and suppressing breast cancer
progression [5]. Another study found that a number of tRNA-derived small RNAs were abundant in
estrogen receptor (ER)-positive breast cancer cell lines, but not in ER negative breast cancer or other
tissue cell lines, suggesting that tRFs are involved in cell proliferation of sex hormone-dependent
cancers [6]. tRFs were also found to be upregulated in trastuzumab-resistant breast cancer cell lines
compared to trastuzumab-sensitive breast cancer and higher levels of tRF expression were correlated
with worse progression-free survival in human epidermal growth factor receptor 2 (HER2) positive
patients, indicating that tRFs are involved in patient response to trastuzumab-targeted therapy in HER2
positive breast cancer [7]. Several tRFs were identified to be predictive biomarkers for recurrence-free
survival in triple-negative breast cancer [8]. Taken together, these findings suggest a functional role of
tRFs in breast cancer development and progression.
CD8+ T cell exhaustion and enhanced regulatory T cell function have been known to be involved
in the progression of human cancer including breast cancer. Once infiltrated T cells are primed and
activated by tumor neoantigens to become effector T cells, they will execute their cytotoxic activities
to kill tumor cells. Neoantigens are present in tumor cells and are generated from tumor-specific
somatic DNA alterations that lead to changes of protein sequences. Neoantigens bind to MHC class
I molecules and then are distinguished by CD8+ T cells, triggering antitumor immunity. Although
tRFs were found to be abundant in immune cells and may play an important role in the immune
response [9,10], the underlying mechanisms are not well understood. One possible mechanism is that
tRFs regulate gene expression within immune cells; and the other can be that tRFs are recognized by
Toll-like receptors to induce the immune responses of Th1 and toxic T lymphocytes [11].
Our previous work reported that the T cell activation score was positively associated with improved
survival in breast cancer patients [12,13]. However, it is unclear whether and how interactions between
expression of tRFs and T cell activation affect breast cancer patient survival. In this study, we aimed to
investigate the effect of tRFs and their interactions with T cell activation status on patient survival in
breast cancer, which will advance the understanding of biological mechanisms of tRFs and serve as
therapeutic targets in breast cancer.
2. Results
2.1. Association of tRFs with Patient Survival
The correlations between expression of each tRF and overall survival were evaluated. A full list of
the 232 tRFs with their sequences and p-value was displayed in Table S1. Among them, fourteen tRFs
with a p-value < 0.05 were selected to include in the multivariate Cox regression model. After model
selection, eight tRFs were retained in the final model, which adjusted for patient’s age at diagnosis,
disease stage, histological type, and T cell activation. Among them, expression levels of three tRFs,
tRFdb-5024a, 5P_tRNA-Leu-CAA-4-1, and ts-49, were positively associated with overall survival, and
two tRFs, ts-34 and ts-58, were negatively associated (Table 1). A higher level of tRFdb-5024a was
significantly associated with decreased risk of death. The adjusted HR was 0.52 (95% CI: 0.37–0.74,
p < 0.001) for high vs. low expression groups. A higher level of 5P_tRNA-Leu-CAA-4-1 was significantly
associated with decreased risk of death. The adjusted HR was 0.55 (95% CI: 0.35–0.87, p = 0.011) for
high vs. low expression groups. A higher level of ts-34 was significantly associated with increased risk
of death. The adjusted HR was 1.62 (95% CI: 1.08–2.44, p = 0.019) for high vs. low expression groups.
A higher level of ts-49 was significantly associated with decreased risk of death. The adjusted HR was
0.40 (95% CI: 0.17–0.93, p = 0.032) for high vs. low expression groups. A higher level of ts-58 was
significantly associated with increased risk of death. The adjusted HR was 1.56 (95% CI: 1.10–2.20,
p = 0.013) for high vs. low expression groups. Patients in the T cell activation group had better overall
survival compared to those in the exhaustion group. The adjusted HR was 0.48 (95% CI: 0.27–0.83,
p = 0.009) for activation vs. exhaustion groups.
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Table 1. Relationships between overall survival and tRNA-derived fragments (tRFs).
Variables
Death
HR 95% CI p-Value
T Cell Activation
Exhaustion 1.00
Activation 0.48 0.27–0.83 0.009
tRFdb-5024a
Low 1.00
High 0.52 0.37–0.74 p < 0.001
5P_tRNA-Leu-CAA-4-1
Low 1.00
High 0.55 0.35–0.87 0.011
ts-34
Low 1.00
High 1.62 1.08–2.44 0.019
ts-49
Low 1.00
High 0.40 0.17–0.93 0.032
ts-58
Low 1.00
High 1.56 1.10–2.20 0.013
tRFdb-1040
Low 1.00
High 1.49 0.93–2.38 0.096
5P_tRNA-Ala-AGC-8-2
Low 1.00
High 1.49 0.99–2.27 0.059
ts-13
Low 1.00
High 1.38 0.94–2.03 0.103
Age (per 5 years) 1.21 1.13–1.29 p < 0.001
Disease Stage
Stage I 1.00
Stage II 2.38 1.31–4.31 0.004
Stage III or IV 7.03 3.84–12.85 p < 0.001
Histological type
Ductal 1.00
Lobular 0.55 0.34–0.87 0.011
Mix 0.59 0.28–1.24 0.161
Other 2.38 1.24–4.57 0.009
2.2. Interaction between T Cell Activation Status and tRFs in Patient Survival
The interactions between T cell activation status and expression of tRFs were evaluated in the
multivariate Cox regression model, with adjustment for patient’s age at diagnosis, disease stage, and
histological type. After model selection, two interaction terms were significant: ts-34 by T cell activation
interaction (p = 0.040) and ts-49 by T cell activation interaction (p = 0.008; Table 2). The other three
tRFs, tRFdb-5024a, 5P_tRNA-Leu-CAA-4-1, and ts-58, remained significantly correlated with overall
survival. A higher level of tRFdb-5024a was associated with decreased risk of death. The adjusted
HR was 0.50 (95% CI: 0.36–0.71, p < 0.001) for high vs. low expression groups. A higher level of
5P_tRNA-Leu-CAA-4-1 was associated with decreased risk of death. The adjusted HR was 0.58
(95% CI: 0.37–0.92, p = 0.021) for high vs. low expression groups. A higher level of ts-58 was associated
with increased risk of death. The adjusted HR was 1.51 (95% CI: 1.07–2.12, p = 0.018) for high vs. low
expression groups.
Cancers 2020, 12, 2230 4 of 16
Table 2. Interactions between T cell activation status and tRFs in the whole sample.
Variables
Death
HR 95% CI p-Value
T Cell Activation
Exhaustion 1.00
Activation 0.60 0.32–1.12 0.110
tRFdb-5024a
Low 1.00
High 0.50 0.36–0.71 p < 0.001
5P_tRNA-Leu-CAA-4-1
Low 1.00
High 0.58 0.37–0.92 0.021
ts-34
Low 1.00
High 2.12 1.40–3.22 p < 0.001
ts-49
Low 1.00
High 0.27 0.10–0.74 0.011
ts-58
Low 1.00
High 1.51 1.07–2.12 0.018
T cell Activation × ts-34 0.22 0.05–0.94 0.040
T cell Activation × ts-49 13.49 2.00–91.02 0.008
Age (per 5 years) 1.20 1.12–1.28 p < 0.001
Disease Stage
Stage I 1.00
Stage II 2.18 1.21–3.94 0.010
Stage III or IV 6.35 3.50–11.52 p < 0.001
Histological type
Ductal 1.00
Lobular 0.53 0.33–0.83 0.006
Mix 0.56 0.26–1.19 0.130
Other 2.60 1.34–5.02 0.005
We further investigated the relationship between survival and expression of tRFs stratified by
T cell activation status (Table 3). In the exhaustion group, patients with a low level of ts-34 showed
better overall survival compared to those with a high level of ts-34 (Figure 1A). The 5-year survival rate
was 0.82 (95% CI: 0.78–0.87) in the low expression group (n = 715) and 0.71 (95% CI: 0.61–0.82) in the
high expression group (n = 174). The adjusted HR was 2.13 (95% CI: 1.40–3.23, p < 0.001) for high vs.
low expression groups. In contrast, among patients in the activation group, there was no significant
difference in overall survival between high and low expression groups (Figure 1B). The 5-year survival
rate was 0.89 (95% CI: 0.81–0.98) in the low expression group (n = 123) and 0.97 (95% CI: 0.90–1.00) in
the high expression group (n = 46). The adjusted HR was 0.18 (95% CI: 0.03–1.14, p = 0.069) for high vs.
low expression groups.
Overall survival in high and low groups of ts-49 was different by T cell activation status.
In the exhaustion group, improved overall survival was observed in patients with a high level of
ts-49 compared to those with a low level of ts-49 (Figure 1C). The 5-year survival rate was 0.79
(95% CI: 0.75–0.84) for the low expression group (n = 841) and 0.89 (95% CI: 0.77–1.00) for the high
expression group (n = 48). The adjusted HR was 0.28 (95% CI: 0.10–0.76, p = 0.013) for high vs. low
expression groups. In contrast, in the activation group, there was no significant difference in overall
survival between high and low expression groups (Figure 1D). The 5-year survival rate was 0.91
(95% CI: 0.85–0.98) for the low expression group (n = 160) and 0.86 (95% CI: 0.63–1.00) for the high
expression group (n = 9). The adjusted HR was 3.91 (95% CI: 0.61–24.95, p = 0.150) for high vs. low
expression groups.
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Table 3. Relationships between overall survival and tRFs stratified by T cell activation status.
Stratification Variable Variables
Death
HR 95% CI p-Value
T cell Exhaustion group tRFdb-5024a
Low 1.00
High 0.51 0.35–0.73 p < 0.001
5P_tRNA-Leu-CAA-4-1
Low 1.00
High 0.54 0.33–0.88 0.014
ts-34
Low 1.00
High 2.13 1.40–3.23 p < 0.001
ts-49
Low 1.00
High 0.28 0.10–0.76 0.013
ts-58
Low 1.00
High 1.58 1.10–2.26 0.013
Age (per 5 years) 1.21 1.13–1.30 p < 0.001
Disease Stage
Stage I 1.00
Stage II 2.60 1.35–4.99 0.004
Stage III or IV 7.18 3.72–13.86 p < 0.001
Histological type
Ductal 1.00
Lobular 0.49 0.30–0.80 0.004
Mix 0.51 0.23–1.12 0.094
Other 2.16 0.98–4.76 0.056
T cell Activation group tRFdb-5024a
Low 1.00
High 0.57 0.15–2.06 0.388
5P_tRNA-Leu-CAA-4-1
Low 1.00
High 0.55 0.12–2.49 0.442
ts-34
Low 1.00
High 0.18 0.03-1.14 0.069
ts-49
Low 1.00
High 3.91 0.61–24.95 0.150
ts-58
Low 1.00
High 0.50 0.14–1.81 0.291
Age (per 5 years) 1.16 0.94–1.43 0.157
Disease Stage
Stage I 1.00
Stage II 0.53 0.11–2.71 0.449
Stage III or IV 4.37 0.74–25.68 0.103
Histological type
Ductal 1.00
Lobular 0.99 0.19–5.32 0.999
Mix 3.65 0.33–40.56 0.292
Other 6.21 1.39–27.71 0.017
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The associations remained significant between overall survival and tRFdb-5024a,
5P_tRNA-Leu-CAA-4-1, and ts-58 in the exhaustion group. The adjusted HRs were 0.51 (95% CI:
0.35–0.73, p < 0.001), 0.54 (95% CI: 0.33–0.88, p = 0.014), and 1.58 (95% CI: 1.10–2.26, p = 0.013),
respectively. In contrast, among patients in the activation group, none of the thre tRFs wer associate
with overall survival.
2.3. Correlation between tRFs and Clinical Pathological Variables
The correlations between the expression o the five tRFs and clinical pathological variables,
i cluding the ER status, PR status, HER2 t tus, histological type, nd disease s age were se sed
(Table S2). Differential expression of tRFdb-5024a was obs rved among different histological types
(p = 2.508 × 10−5). ts-34 was differentially expressed between ER positive and negative groups (p = 1.691
× 10−6), between PR positive and negative groups (p = 1.424 × 10−5), and between HER2 positive and
negative groups (p = 0.023). ts-58 was differentially expressed between HER2 positive and negative
groups (p = 1.473 × 10−4). There was a borderline significant association between disease stage and
ts-49 (p = 0.055). 5P_tRNA-Leu-CAA-4-1 was not differentially expressed between any groups of the
clinical variables.
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2.4. Correlation between tRFs and mRNA Transcripts
The correlations between the five tRFs and 36,674 mRNA transcripts were assessed. We identified
404 positively and 2292 negatively correlated genes with tRFdb-5024a, 16 positively and 2 negatively
correlated genes with 5P_tRNA-Leu-CAA-4-1, 310 positively and 230 negatively correlated genes with
ts-34, and 280 positively and 1 negatively correlated genes with ts-58. No genes were significantly
correlated with ts-49. Pathway enrichment analyses were carried out on positively and negatively
correlated genes for the four tRFs separately. For tRFdb-5024a, the positively correlated genes were
enriched for 27 pathways and the negatively correlated genes were enriched for 405 pathways
(Table S3). Cell cycle related pathways were found in the top 10 pathways enriched in the positively
correlated genes (Figure 2A). The top 10 pathways enriched in the negatively correlated genes included
epithelial-to-mesenchymal transition (EMT), signal transduction, cell adhesion ECM remodeling,
and extracellular matrix-regulated proliferation related pathways (FDR = 4.05 × 10−12, 1.40 × 10−8,
1.48 × 10−8, and 1.77 × 10−8, respectively; Figure 2B and for Table S3). For ts-34, the positively
correlated genes were enriched for 33 pathways and the negatively correlated genes were enriched for
13 pathways (Table S4). The positively correlated genes were enriched for molecules involved in cell
cycle related pathways (Figure 2C), while the negatively correlated genes were involved in mammary
cell development and neuronal cell development (Figure 2D). Notably, the most relevant pathway
was breast cancer (general schema) pathway in which three genes were negatively correlated with
ts-34 (FDR = 2.95 × 10−2). For ts-58, four pathways were enriched in the positively correlated genes
and no significant pathways were found in the negatively correlated genes (Table S5). The top two
pathways were development microRNA-dependent regulation of EMT pathway (FDR = 5.48 × 10−6)
and TGF-beta signaling via microRNA in the breast cancer pathway (FDR = 3.94 × 10−3; Figure 2E).
No significant pathways were identified for ts-49 and 5P_tRNA-Leu-CAA-4-1.
2.5. Correlation between tRFs and Gene Modules
Gene co-expression network was constructed to identify modules of highly correlated genes using
weighted gene co-expression network analysis (WGCNA). The identified 38 gene modules and their
correlations with expression of the five tRFs were demonstrated in Figure 3A. For tRFdb-5024a, the pink
module was the top positively correlated module (r = 0.13, p = 3 × 10−5) and the yellow module was
the top negatively correlated module (r = -0.27, p = 1 × 10−19). For 5P_tRNA-Leu-CAA-4-1, the top
positively correlated module was the blue module (r = 0.11, p = 5 × 10−4). For ts-34, the pink module
was the top positively correlated module (r = 0.18, p = 5 × 10−9) and the black module was the top
negatively correlated module (r = -0.16, p = 2 × 10−7). For ts-58, the top positively correlated module
was the green-yellow module (r = 0.16, p = 2 × 10−7). Weak correlations were observed for modules
that were negatively correlated with 5P_tRNA-Leu-CAA-4-1 and ts-58, which were consistent with
the observation that genes were mostly positively correlated with 5P_tRNA-Leu-CAA-4-1 and ts-58.
No modules were significantly correlated with ts-49. Figure 3B shows the correlations between gene
modules and clinical pathological variables. The pink module was significantly correlated with ER
status (r = −0.52, p = 2 × 10−70), PR status (r = −0.45, p = 9 × 10−52), ductal subtype (r = 0.31, p = 2 ×
10−25), and lobular subtype (r = −0.32, p = 8 × 10−27). The yellow module was significantly associated
with ductal subtype (r = −0.3, p = 1 × 10−23) and lobular subtype (r = 0.34, p = 4 × 10−30). Black
module was significantly correlated with ER status (r = 0.65, p = 1 × 10−122) and PR status (r = 0.57,
p = 2 × 10−85). These results, combined with the significant associations between the tRFdb-5024a and
histological type, ts-34 and ER or PR status, suggested potential biological functions of tRFdb-5024a
and ts-34 in breast cancer.
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Figure 2. Top gene pathways associated with tRFs. Top 10 pathways from the positively (A) and
negatively (B) correlated genes of tRFdb-5024a, positively (C) and negatively (D) correlated genes of
ts-34, and positively correlated genes of ts-58 (E).
The pathway enrichment analysis was conducted to evaluate the biological function of top gene
modules associated with the five tRFs. There were 80, 197, 159, 31, and 6 pathways enriched in
pink, yellow, blue, black, and green-yellow modules, respectively (Table S6). For tRFdb-5024a, genes
in the pink module were largely enriched for cell cycle related pathways (Figure 4A), consistent
with the pathway results of the positively correlated genes of tRFdb-5024a. The signal transduction
pathway enriched in the negatively correlated genes of tRFdb-5024a was also observed in the top 10
pathways of yellow modules (Figure 4B). For 5P_tRNA-Leu-CAA-4-1, blue module (22 genes) was
enriched for ubiquinone metabolism pathway (FDR = 3.72 × 10−10; Figure 4C and Table S6). Genes
such as NDUFB1, NDUFB2, and NDUFB7 were found to have significant prognostic values for breast
cancer patients [14]. For ts-34, pathway results of the pink module revealed that many of the top 10
pathways were related to the cell cycle function (Figure 4A), consistent with the pathway results of the
positively correlated genes of ts-34. The breast cancer (general schema) pathway was among the top
10 pathways of the black module (Figure 4D), consistent with the pathway results of the negatively
correlated genes of ts-34. Interestingly, genes in the black module were enriched for the PR action in
breast cancer: stimulation of cell growth and proliferation pathway (FDR = 9.05 × 10−3), inhibition
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of LKB1/AMPK signaling in breast cancer pathway (FDR = 1.37 × 10−2), and IL-6 signaling in breast
cancer cells pathway (FRD = 2.48 × 10−2) (Figure 4D and Table S6). For ts-58, the top two significant
pathways of green-yellow module (Figure 4E), development MicroRNA-dependent regulation of EMT
and TGF-beta signaling via microRNA in breast cancer, agreed well with the pathway results of the
positively correlated genes of ts-58.Cancers 2020, 12, x 9 of 16 
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Figure 3. Correlation of gene modules with tRFs and clinical pathological variables. Row represents
module eigengenes, column represents tRFs or clinical variables. Each cell displays the corresponding
correlation coefficient and p-value. (A) Heatmap of correlations between module eigengenes
and expression of the five tRFs. (B) Heatmap of correlations between module eigengenes and
clinical variables.
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3. Discussion
tRFs have been found to be dysregulated in several human cancers, such as prostate, colon, lung,
and breast canc r [8,15–18]. Howev r, understanding of the biologi al mechani ms of tRFs in cancer
is still in its infancy. In this study, we explored the effect of tRFs and th ir interacti ns with the T
ce activation score on patient survival in breast cancer. We al o identified g nes and modules that
were asso iated with tRFs. Pathway en ichment r sults provided valuable insights int the functions
of tRFs.
To our knowledge, this is the first attempt to investigate how interactions between expression
of tRFs and T cell activation status affect breast cancer patient survival using a large cohort available
in TCGA. We integrated multiple data types, including mRNA, tRFs, and clinical information. Our
results suggest that tRFdb-5024a, 5P_tRNA-Leu-CAA-4-1, and ts-49 were positively associated with
patient survival, while ts-34 and ts-58 were negatively associated. ts-34 and ts-49 showed significant
interactions with T cell activation status. In the T cell exhaustion group, better overall survival was
observed in patients with a low level of ts-34 and a high level of ts-49. However, there was no significant
difference in overall survival between high and low expression groups of ts-34 and ts-49 in the T
cell activation group. These findings suggest that tRFs affect patient survival differently depending
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on the T cell activation status. We also observed that tRFdb-5024a was significantly associated with
the histological type; ts-34 was significantly associated with ER, PR, and HER2 status; and ts-58 was
significantly associated with HER2 status. These results added to the evidence of biological functions
of tRFdb-5024a, ts-34, and ts-58 in breast cancer.
Spearman correlation analysis demonstrated that tRFdb-5024a mainly downregulates gene
expression, whereas 5P_tRNA-Leu-CAA-4-1, ts-34, and ts-58 upregulate gene expression. Gene
modules associated with the breast cancer-related tRFs appeared to be involved in various biological
processes in human cancer, including cell cycle, EMT, extracellular matrix-regulated proliferation,
signal transduction, neuronal cell development, and mammary cell development. Our study showed
that negatively correlated genes with tRFdb-5024a (e.g., TGF-beta1 and TGF-beta3) were enriched for
development regulation of the EMT pathway and extracellular matrix-regulated proliferation related
pathway. EMT is a hallmark of human cancer with the acquisition of cancer stem cell-like traits that
promote cancer progression and metastasis [19]. Extracellular matrix is a major structural component
of the tumor microenvironment and serves as a niche for cancer stem cells. It influences the recruitment
of immune cells, impairs proliferation and activation of T cells, and induces EMT [20]. Previous studies
showed that extracellular matrix-dependent disruption of cell adhesion could lead to increased cell
motility and circulating tumor cells, consequently resulting in elevated relapse and mortality risk in
breast cancer [21,22]. The cell cycle role of APC in the cell cycle regulation pathway was enriched
in both positively correlated genes of tRFdb-5024a and ts-34, suggesting that tRFdb-5024a and ts-34
may target different genes in the cell cycle pathway. Cell cycle-related genes include oncogenes
and tumor suppressor genes. For example, Anaphase-Promoting Complex or Cyclosome (APC/C)
is an E3 ubiquitin ligase and functions as a tumor suppressor by degrading CDKs [23], whereas
high expression of CDK1 was previously reported to be correlated with poor survival [24]. Thus,
it warrants further investigation of which distinct target gene(s) in the cell cycle pathway is targeted
by tRFdb-5024a and ts-34. Interestingly, we found that ts-34 downregulated genes were enriched for
breast cancer (general schema) pathway, where absent expression of PGR was correlated with poor
survival [25]. Similarly, the WGCNA analysis showed that the ts-34 negatively correlated black module
was enriched for the PR action in breast cancer: stimulation of cell growth and proliferation pathway.
Absent expression of ESR1 and/or PGR showed resistance to hormonal therapy and higher risk of
mortality [25,26]. The top two significant pathways, development microRNA-dependent regulation
of EMT and TGF-beta signaling via microRNA in breast cancer, were enriched in both the positively
correlated genes and green-yellow module of ts-58. This is consistent with the reports in the previous
studies that high expression of TGF-beta and miR-21 was positively associated with poor prognosis
in breast cancer [27,28]. The underlying mechanisms may involve the upregulation of development
microRNA-dependent regulation of the EMT pathway and TGF-beta signaling via microRNA in
breast cancer, which increases metastasis by promoting EMT [29]. In addition, the WGCNA results
demonstrated new insights into potential functions of 5P_tRNA-Leu-CAA-4-1. The top significant
pathway, ubiquinone metabolism pathway, was enriched in the positively correlated blue module of
5P_tRNA-Leu-CAA-4-1, where high expression of NDUFB2 had a better prognostic value in breast
cancer patients [14]. Figure 5 illustrates a schematic pathway diagram that presents the potential
molecular mechanisms of vital-associated tRFs in breast cancer in this study. The biological functions
of ts-49 remains to be explored in the future.
There are several caveats and limitations in this study. First, molecular subtype information
is available on a small subset of patients, preventing us from incorporating it into the analysis.
Whether and how the effect of tRFs and their interactions with the T cell activation status on patient
survival varying with different molecular subtypes remains to be investigated in the future. Second,
chemotherapy information is unavailable in this study so that we cannot include chemotherapy as
a covariate in the multivariate Cox regression models. Thus, interpretation and generalization of
the results need to be cautious. However, as the standard care for breast cancer is surgical resection
followed by adjuvant chemotherapy for all patients except for those who were too sick to tolerate
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chemotherapy, leading to a relatively small proportion of patients without chemotherapy in clinic
practice, our results might be robust given that the sample size is relatively large in this study.Cancers 2020, 12, x 12 of 16 
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4. Materials and Methods
4.1. Study subjects and Data Sources
Included in this study were 1081 female patients with primary breast cancer. Their clinical
data were obtained from The Cancer Genome Atlas (TCGA) breast invasive carcinoma study [30].
The normalized RNA sequencing data were downloaded from the TCGA-BRCA project in Genomic
Data Commons (GDC) data portal [31], which provided expression levels of 60,483 mRNA transcripts.
T cell activation scores were computed based on 13 genes related to T cell activation status (NKG7,
CCL4, CST7, PRF1, GZMA, GZMB, IFNG, CCL3, PD-1, TIGIT, LAG3, TIM3, and CTLA4), as described
previously [12]. To obtain expression of tRFs, small RNA raw sequencing reads were processed for
quality control and then realigned to the human reference genome (hg19) and the human genomic
tRNA database [32,33]. We used normalized count matrix consisting of 232 distinct tRFs from the
tRFexplorer database in our analysis [34,35].
One thousand and fifty-eight patients had clinical, mRNA gene expression, and tRFs data, and
were retained for further analysis. The average age at diagnosis was 58.4 (range: 26–90) years old.
Among the 1048 patients with disease stage information, most were diagnosed with breast cancer
at an early stage including 178 (17.0%) at stage I and 600 (57.3%) at stage II. The other 270 patients
(25.7%) were diagnosed at an advanced stage (III or IV). There were 1056 patients with histological
type information: 71.5% (n = 755) ductal carcinoma, 18.8% (n = 198) lobular, 4.9 % (n = 52) mix, and
4.8% (n = 51) other. Among the 1009 women with a known ER status, 77.0% (n = 777) were positive
and 23.0% (n = 232) were negative. Among the 1006 patients with a known progesterone receptor (PR)
status, 67.0% (n = 674) were positive and 33.0% (n = 332) were negative. There are 700 patients with
HER2 information: 22.3% (n = 156) were positive and 77.7% (n = 544) were negative. The average
length of follow-up in the 1058 patients was 40.8 (range: 0–282.7) months and 147 patients died during
the follow-up period.
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4.2. Statistical Analyses
Multivariate Cox proportional hazards models were used to evaluate the relationship between
the expression of tRFs and overall survival, adjusting for covariates including the patient’s age at
diagnosis, disease stage, histological type, and T cell activation status. Both the expression of tRFs and
the T cell activation score were treated as categorical variables in the analysis. For each tRF, patients
were classified into two groups, high and low, with the cutoff value to be the median of the expression
level. T cell activation status, activation or exhaustion, was defined as previously described [12].
We first selected a small set of tRFs with a p-value < 0.05 by the Cox regression model with a single tRF
adjusting for covariates. Then the multivariate Cox model with backward elimination was conducted
to select significant tRFs and obtain adjusted hazards ratios (HRs) with 95% confidence intervals
(95% CIs). The interaction between T cell activation status and expression of tRFs were evaluated by
including it in the Cox regression model as an interaction term. Backward elimination using Akaike
information criterion was performed for model selection. We also assessed effects of tRFs on overall
survival in each subgroup stratified by the T cell activation status using Kaplan–Meier survival curves.
Proportional hazards assumption was examined in the analysis. For each clinical pathological variable,
Wilcoxon test and Kruskal–Wallis test were used to evaluate differential expression of tRFs between
patients from different pathological categories. In all statistical analyses, p-value less than 0.05 was
considered to be significant. All analyses were performed in R [36].
4.3. Functional Pathway Analysis
To understand the biological functions of tRFs in breast cancer progression, we performed
functional pathway analysis using the MetaCore software [37]. Spearman correlation analysis was
carried out to assess correlations between significant tRFs identified in the Cox regression models
and mRNA expression levels. Positively and negatively correlated genes with a Bonferroni corrected
p-value < 0.05 were included in a pathway analysis separately. We also performed WGCNA to
construct gene correlation networks and identify modules of highly correlated genes [38]. In the
WGCNA analysis, we first excluded genes with no variation (standard deviation of fragments per
kilobase million (FPKM) = 0) or with low expression (FPKM < 0.05) in 90% of the samples. Then, we
clustered patients based on their gene expression profiles and removed sample outliers. Lastly, we
applied WGCNA with the default setting to obtain gene modules and their correlation with significant
tRFs and clinical pathological variables. Genes in top modules with the highest positive or negative
correlation coefficients with each tRF and p-value < 0.001 were selected for the pathway analysis.
Fisher’s exact test was used to determine whether a gene module is enriched for a functional pathway.
Pathways with a false discovery rate (FDR) < 0.05 were considered to be significant. We reported
pathways that are significant and more than one gene overlapped with the gene module [39].
5. Conclusions
In this study, we integrated multiple data types to elucidate the effect of tRFs and their interactions
with T cell activation score on patient survival in breast cancer and to uncover the biological relevance
of tRFs with statistical significance. We identified five tRFs that were significantly associated with
patient survival in breast cancer, especially in the T cell exhaustion group, suggesting that these
five tRFs are potential therapeutic targets to improve patient survival, and may have implication in
improving immunotherapy in breast cancer. Moreover, our results provided novel knowledge in
biological functions of the tRFs in breast cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2230/s1,
Table S1: A full list of tRFs with their sequences and p-value, Table S2: Differential expression of tRFs between
patients from different pathological categories, Table S3: Significant pathways enriched in positively and negatively
correlated genes of tRFdb-5024a, Table S4: Significant pathways enriched in positively and negatively correlated
genes of ts-34, Table S5: Significant pathways enriched in positively correlated genes of ts-58, Table S6: Significant
pathways enriched in pink, yellow, blue, black, and green-yellow modules.
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